公开(公告)号：US07172762B1

公开(公告)日：2007-02-06

申请号：US09489711

申请日：2000-01-24

Applicant: David S. Roberts ,  Leroy A. Swearingin ,  Brian T. Suiter

Inventor： David S. Roberts ,  Leroy A. Swearingin ,  Brian T. Suiter

IPC: A61K39/02 ,  A61K39/00 ,  A01N63/00

CPC classification number: A61K39/0241 ,  A61K2039/521 ,  A61K2039/55566 ,  Y10S424/825 ,  Y10S530/825

Abstract: The invention relates to stabilized antigen compositions of Erysipelothrix rhusiopathiae and vaccine formulations containing such antigen compositions. Antigens of the invention are effective in providing long-term protection against erysipelas in animals.

Abstract translation: 本发明涉及Erysillolothrix rhusiopathiae的稳定化抗原组合物和含有这种抗原组合物的疫苗制剂。 本发明的抗原在动物中有效地提供对丹毒的长期保护。

公开(公告)号：US20070020296A1

公开(公告)日：2007-01-25

申请号：US11507231

申请日：2006-08-21

Applicant: Hsien-Jue Chu ,  Wumin Li ,  Zhichang Xu

Inventor： Hsien-Jue Chu ,  Wumin Li ,  Zhichang Xu

IPC: A61K39/116 ,  A61K39/02

CPC classification number: A61K39/0241 ,  A61K2039/521 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  Y10S424/825 ,  A61K2300/00

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract translation: 本发明提供了一种改良的猪肺炎支原体疫苗组合物，其在单次给药后有利地提供免疫感染。 组合物包含灭活的猪肺炎支原体疫苗和佐剂混合物，其组合在单次施用后提供对猪肺炎支原体感染的免疫，并引起对猪肺炎支原体菌苗特异性的免疫应答，并且包括细胞介导的免疫和局部（分泌型IgA ）免疫力。 在优选的实施方案中，佐剂混合物包含丙烯酸聚合物，最优选的是CARBOPOL，以及可代谢的油如一种或多种不饱和萜烯烃，优选角鲨烯或角鲨烷的混合物，以及聚氧乙烯 - 聚氧丙烯嵌段共聚物 作为PLURONIC（R）。 疫苗组合物可以任选地包括防腐剂，优选硫柳汞和/或EDTA。

公开(公告)号：US20060257414A1

公开(公告)日：2006-11-16

申请号：US10520833

申请日：2003-07-10

Applicant: Stanley Kleven ,  Naola Ferguson

Inventor： Stanley Kleven ,  Naola Ferguson

IPC: A61K39/00 ,  A61K39/38

CPC classification number: C12R1/35 ,  A61K39/0241 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/544 ,  A61K2039/552

Abstract: The present invention provides a protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract translation: 本发明提供一种保护性制剂，其可以防止鸡尾草杆菌中的毒性毒蕈碱性支原体感染。 制剂包含保护量的活MG菌株K5054或其药学上可接受的载体中的衍生物。 还提出了一种能够预防鸡尾草属鸡的毒性支原体感染疫苗。 还提供了施用制剂和疫苗的方法。

公开(公告)号：US20060171960A1

公开(公告)日：2006-08-03

申请号：US11321389

申请日：2005-12-29

Applicant: Hsien-Jue Chu ,  Wumin Li

Inventor： Hsien-Jue Chu ,  Wumin Li

IPC: A61K39/295

CPC classification number: A61K39/0241 ,  A61K9/0095 ,  A61K2039/522 ,  A61K2039/542 ,  A61K2039/552

Abstract: The present invention encompasses methods and compositions both for providing protection against disease in an animal and for inducing increased intake of an orally administered vaccine by an animal. The methods of the invention are directed to admixing a bacterial or viral antigen with a water soluble palatable flavorant, further admixing the antigen and flavorant mixture with a water soluble vehicle for oral administration of the vaccine to an animal in order to provide protection against disease associated with infection by the admixed antigen and to induce the increased intake of the vaccine with the flavorant. The present invention thus encompasses methods and compositions for the oral vaccination of healthy animals through drinking water or syrups as an aid in the prevention of disease. The admixing of the palatable flavorant provides for a vaccine formulation with a desirable taste in order to promote self-administration of the vaccine formulation and/or to prevent rejection of the formulation when administered by an animal handler.

公开(公告)号：US07018638B2

公开(公告)日：2006-03-28

申请号：US10150597

申请日：2002-05-17

Applicant: Hsien-Jue Chu ,  Wumin Li ,  Zhichang Xu

Inventor： Hsien-Jue Chu ,  Wumin Li ,  Zhichang Xu

IPC: A61K39/295

CPC classification number: A61K9/0024 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K47/06 ,  A61K47/10 ,  A61K47/32 ,  A61K2039/521 ,  A61K2039/525 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/16134 ,  Y02A50/48

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Abstract translation: 本发明提供了一种改良的猪肺炎支原体疫苗组合物，其在单次给药后有利地提供免疫感染。 组合物包含灭活的猪肺炎支原体疫苗和佐剂混合物，其组合在单次施用后提供对猪肺炎支原体感染的免疫，并引起对猪肺炎支原体菌苗特异性的免疫应答，并且包括细胞介导的免疫和局部（分泌型IgA ）免疫力。 在优选的实施方案中，佐剂混合物包含丙烯酸聚合物，最优选的是CARBOPOL，以及可代谢的油如一种或多种不饱和萜烯烃，优选角鲨烯或角鲨烷的混合物，以及聚氧乙烯 - 聚氧丙烯嵌段共聚物 作为PLURONIC（R）。 疫苗组合物可以任选地包括防腐剂，优选硫柳汞和/或EDTA。 在另一个实施方案中，本发明提供了改进的猪肺炎支原体疫苗组合物，其有利地在单次施用后提供免疫感染，并且包含灭活的猪肺炎支原体菌苗和佐剂或佐剂混合物，其组合提供猪肺炎支原体 单次给药后感染，并引起特异于猪肺炎支原体菌的免疫应答，并与其他疫苗组分结合使用，包括细胞介导的免疫和局部（分泌型IgA）免疫。

公开(公告)号：US20050079185A1

公开(公告)日：2005-04-14

申请号：US10899181

申请日：2004-07-26

Applicant: Alexis Guy Parisot ,  Stephanie Desgouilles-Blechet ,  Catherine Charreyre

Inventor： Alexis Guy Parisot ,  Stephanie Desgouilles-Blechet ,  Catherine Charreyre

IPC: A61K39/102 ,  A61K39/12 ,  A61K39/145 ,  A61K39/295 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K39/0241 ,  A61K39/102 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/55 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N2750/10034 ,  C12N2760/16134

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. In one embodiment, the present invention provides for an injectable oil-in-water (O/W) emulsion comprising: (1) an aqueous solution containing an immunogen, said immunogen selected from the group comprising an inactivated Mycoplasma hyopneumoniae bacterium, an inactivated porcine circovirus type 2 (PCV-2) virus or combinations thereof; (2) a mineral oil; (3) a non-ionic lipophilic surfactant; and (4) a non-ionic hydrophilic surfactant having a low HLB value which comprises ethoxylated fatty acid diesters of sorbitan (generally having HLB value between 11 and 13). In another preferred embodiment, the present invention provides for an injectable oil-in-water (O/W) emulsion comprising: (1) an aqueous solution containing an immunogen; (2) a non-ionic hydrophilic surfactant having a high hydrophilic-lipophilic balance (HLB) value greater than 13 and less than 40, in particular HLB≧13.5, and preferably HLB≧14; (3) a mineral oil; (4) a non-ionic lipophilic surfactant; and (5) a non-ionic hydrophilic surfactant having a low HLB value (HLB value of about 9 to about 13).

Abstract translation: 本发明提供了一种新型的水包油（O / W）乳液，其在细菌或病毒悬浮液的存在下具有增加的稳定性，特别是浓缩和未纯化或弱纯化的那些。 本发明的乳液可用作递送包含至少一种免疫原的药物组合物，特别是选自包含灭活病原体，减毒病原体，亚单位，重组表达载体的免疫原的载体， 和质粒或其组合。 在一个实施方案中，本发明提供了一种可注射的水包油（O / W）乳液，其包含：（1）含有免疫原的水溶液，所述免疫原选自灭活的猪肺炎支原体细菌，灭活的猪 2型圆环病毒（PCV-2）病毒或其组合; （2）矿物油; （3）非离子型亲脂性表面活性剂; 和（4）具有低HLB值的非离子亲水性表面活性剂，其包含脱水山梨糖醇的乙氧基化脂肪酸二酯（通常HLB值在11和13之间）。 在另一个优选实施方案中，本发明提供了一种可注射的水包油（O / W）乳液，其包含：（1）含有免疫原的水溶液; （2）具有大于13且小于40，特别是HLB> = 13.5，优选HLB> = 14的高亲水亲油平衡值（HLB）值的非离子亲水性表面活性剂; （3）矿物油; （4）非离子型亲脂性表面活性剂; 和（5）具有低HLB值（HLB值约9至约13）的非离子亲水性表面活性剂。

公开(公告)号：US20050053627A1

公开(公告)日：2005-03-10

申请号：US10726029

申请日：2003-12-02

Applicant: Joan Leonard ,  Robert Tully

Inventor： Joan Leonard ,  Robert Tully

IPC: A61K39/00 ,  A61K20060101 ,  A61K39/02 ,  A61K39/04 ,  A61K39/295 ,  A61K39/39 ,  A61P20060101 ,  A61P31/00 ,  A61P31/04 ,  A61P37/04

CPC classification number: A61K39/0241 ,  A61K2039/521 ,  A61K2039/522 ,  A61K2039/552 ,  A61K2039/555 ,  A61K2039/55505 ,  A61K2039/55566

Abstract: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

Abstract translation: 描述了用于牛用于牛支原体的新型有效疫苗的发明。 这些疫苗不表现出不希望的副作用，并且防止牛分枝杆菌相关疾病，如传染性乳腺炎，呼吸性肺炎，关节感染，角膜结膜炎和中耳感染。 新型疫苗也可以减少牛分枝杆菌感染对牛奶生产，体重增加和动物健康的影响。 还公开了将牛分枝杆菌感染特征化和诊断为特异性生物型的方法。 根据本发明制备的疫苗组合物可以是减毒或灭活的品种。 疫苗还可以包括来自其他病原体的抗原，以便对除牛分枝杆菌引起的疾病以外的疾病提供保护性的免疫原性应答。

公开(公告)号：US20030064079A1

公开(公告)日：2003-04-03

申请号：US10177860

申请日：2002-06-20

Applicant: Pfizer Inc.

Inventor： Alexander C. Goudie ,  Andrew Raymond Peters ,  Robin Lee Keich

IPC: A61K039/04

CPC classification number: A61K39/0241 ,  A61K2039/521 ,  A61K2039/552 ,  A61K2039/55566 ,  Y10S435/87

Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma bovis (M. bovis) by administering to the animal an effective amount of a Mycoplasma hyopneumoniae (M. hyo) vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

Abstract translation: 本发明涉及通过向动物施用有效量的猪肺炎支原体（M.hoo）疫苗来治疗或预防由牛支原体感染引起的动物疾病或病症的方法。 M.hoo疫苗可以是全部或部分细胞灭活或修饰的活体制剂，亚单位疫苗或核酸或DNA疫苗。 可以合成或重组生产根据本发明施用的猪尾杆菌疫苗。

公开(公告)号：US5565205A

公开(公告)日：1996-10-15

申请号：US568427

申请日：1990-08-16

Applicant: Gary R. Petersen ,  K. I. Dayalu

Inventor： Gary R. Petersen ,  K. I. Dayalu

IPC: A61K39/00 ,  A01N63/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/39 ,  A61P31/04 ,  C12N1/20 ,  C12N1/36 ,  C12N1/38 ,  C12R1/35

CPC classification number: A61K39/0241 ,  A61K2039/521 ,  A61K2039/552 ,  Y10S424/825

Abstract: This invention provides a bacterin comprising a virulent Mycoplasma hyopneumoniae isolate, inactivated with binary ethyleneimine, in an amount effective to immunize a swine against infection by Mycoplasma hyopneumoniae and a suitable physiologically acceptable carrier. The invention also provides a method of producing this bacterin. The invention further provides a method of inactivating a virulent strain of Mycoplasma hyopneumoniae by contacting the Mycoplasma hyopneumoniae with binary ethyleneimine. Finally, the invention also provides a method of immunizing swine against infection by Mycoplasma hyopneumoniae comprising administering to the swine a dose of the bacterin so as to immunize the swine.

Abstract translation: 本发明提供了一种含有毒力的猪肺炎支原体分离物的菌苗，其以二元乙烯亚胺灭活，其量可有效地免疫猪免受猪肺炎支原体感染和合适的生理上可接受的载体。 本发明还提供了一种生产该菌苗的方法。 本发明还提供了通过使猪肺炎支原体与二元乙烯亚胺接触来灭活猪肺炎支原体毒性菌株的方法。 最后，本发明还提供了免疫猪抵抗猪肺炎支原体感染的方法，包括向猪施用一定剂量的菌苗以免疫猪。

公开(公告)号：US5534413A

公开(公告)日：1996-07-09

申请号：US57168

申请日：1993-05-04

Applicant: Shyh-Ching Lo ,  Richard Y. Wang ,  Michael M. Hayes

Inventor： Shyh-Ching Lo ,  Richard Y. Wang ,  Michael M. Hayes

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  C07K14/30 ,  C12N7/00 ,  G01N33/569 ,  C12Q1/04 ,  C07K16/12

CPC classification number: C12N7/00 ,  A61K39/0241 ,  C07K14/30 ,  C12R1/35 ,  G01N33/56933 ,  G01N33/56988 ,  A61K39/00 ,  C12N2740/16011 ,  Y10S435/87 ,  Y10S435/974 ,  Y10S435/975

Abstract: The present invention relates to a novel mycoplasma isolated from the urine of patients with AIDS. The mycoplasma has unique morphological and pathobiological properties. The invention also relates to the antigens and antibodies of the novel mycoplasma, and methods of detection utilizing these antigens and antibodies. Antigenically and genetically, the mycoplasma is distinct from all other known mycoplasmas.

Abstract translation: 本发明涉及从艾滋病患者的尿中分离的新型支原体。 支原体具有独特的形态和病理特性。 本发明还涉及新型支原体的抗原和抗体，以及利用这些抗原和抗体的检测方法。 抗原和遗传上的支原体与所有其他已知的支原体不同。